Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07247110 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
A Phase 1 study of Malignant Neoplasm, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 250
- Enrollment target
- 9
- Study locations
NCT07247110 is a Phase 1 study of Malignant Neoplasm that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 250 participants, below the 509-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (51% lower). The trial reports 9 study locations across 4 states.
The verdict
NCT07247110, a Phase 1 study of Malignant Neoplasm, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 250 participants
- Enrollment target
- 9
- Study locations
Study Summary
Researchers are looking for new ways to treat certain advanced or metastatic solid tumors. The goal of this study is to learn about the safety of MK-4716 and if people tolerate it when taken alone or with other treatments.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL Cetuximab
- DRUG MK-4716
Study Locations (9)
Other
- Rambam Health Care Campus ( Site 0252) - Haifa
- Rabin Medical Center ( Site 0253) - Petah Tikva
- Sheba Medical Center ( Site 0251) - Ramat Gan
- Hospital General Universitari Vall d Hebron ( Site 0360) - Barcelona
- Hospital Clinic de Barcelona ( Site 0362) - Barcelona
- Hospital Universitario Fundacion Jimenez Diaz ( Site 0361) - Madrid
Texas
- NEXT Oncology ( Site 0051) - Irving
Virginia
- NEXT Virginia ( Site 0054) - Fairfax
Western Australia
- One Clinical Research ( Site 0454) - Nedlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2025-12-16 |
| Est. Completion | 2030-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07247110
The ClinicalTrials.gov registry entry for NCT07247110 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 509-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (51% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malignant Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT07247110 reports 9 study locations spanning 4 distinct geographic areas - top geographies include Other, Texas, Virginia.
Frequently Asked Questions
What is clinical trial NCT07247110 about?
NCT07247110 is a clinical study titled "A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)". Researchers are looking for new ways to treat certain advanced or metastatic solid tumors. The goal of this study is to learn about the safety of MK-4716 and if people tolerate it when taken alone or with other treatments.
What is the current status of trial NCT07247110?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 250 participants. The study started on 2025-12-16. Estimated completion is 2030-12-01.
What conditions does trial NCT07247110 study?
This clinical trial studies the following conditions: Malignant Neoplasm.
What interventions are being tested in trial NCT07247110?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Cetuximab (BIOLOGICAL), MK-4716 (DRUG).
Who is sponsoring clinical trial NCT07247110?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07247110 being conducted?
This trial has 9 study locations across Texas, Virginia, Western Australia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
RECRUITING · Phase 1
-
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
RECRUITING · Phase 1
-
HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases
ACTIVE NOT RECRUITING · Phase 1
-
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.